The flip side of the hot IPO market? A chill could trigger a sudden cash crunch in biotech, followed by more deals

Over the last 5 years biotech IPOs and follow-ons have raised a tsunami of cash totaling some $128 billion, according to a new estimate out from Leerink. And these newly coined public players have been spending money fast.